Immunotherapy shows clinical benefit in relapsed transplant recipients
Tuesday, December 9, 2014 - 16:32
in Health & Medicine
A multicenter phase 1 trial of the immune checkpoint blocker ipilimumab found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation, according to investigators.